4 quarters tracked · Beat rate 100% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $2.65 | $2.65 | +0.2% | Beat |
| Q4 2025 | 2025-12-31 | $2.71 | $2.71 | +0.2% | Beat |
| Q3 2025 | 2025-09-30 | $1.81 | $1.86 | +2.7% | Beat |
| Q2 2025 | 2025-06-30 | $2.94 | $2.97 | +0.9% | Beat |
Earnings Beat Rate
AbbVie has beaten analyst EPS estimates in 4 of 4 tracked quarters (100% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →